- Home
- CUE vs VERI Comparison
CUE vs VERI Comparison
Compare CUE & VERI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CUE | VERI |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 142.2M |
| IPO Year | 2017 | 2017 |
Fundamental Metrics
Financial Performance| Metric | CUE | VERI |
|---|---|---|
| Price | $25.80 | $1.53 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $120.00 | $7.00 |
| AVG Volume (30 Days) | 71.2K | ★ 2.7M |
| Earning Date | 05-13-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.11 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $27,466,000.00 | ★ $92,637,000.00 |
| Revenue This Year | N/A | $52.20 |
| Revenue Next Year | N/A | $3.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $1.29 |
| 52 Week High | $41.42 | $9.42 |
Technical Indicators
Market Signals| Indicator | CUE | VERI |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 31.72 |
| Support Level | $0.30 | N/A |
| Resistance Level | $32.60 | $2.35 |
| Average True Range (ATR) | 3.67 | 0.13 |
| MACD | -0.48 | -0.04 |
| Stochastic Oscillator | 53.77 | 2.26 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About VERI Veritone Inc.
Veritone Inc is a provider of artificial intelligence (AI) computing solutions and services. It generates revenue through the delivery of its Software Products and Services which consists of revenues generated from Commercial Enterprise and Government and Regulated Industries customers using the company's aiWARE platform and hiring solutions, any related support and maintenance services, and any related professional services associated with the deployment and/or implementation of such solutions, Managed Services which consist of revenues generated from Commercial Enterprise customers using company's content licensing services, advertising agency, influencer management and related services. It has presence in the United States, the United Kingdom, France, Australia, Israel, and India.